Cell & Gene therapy

The term "autologous" is most frequently found in the context of cell therapy. In this article, we will therefore take a closer look at this revolutionary therapeutic approach.

What does "allogeneic" mean, precisely? How do allogeneic cell therapies work, and what is the difference to autologous approaches? Questions like these will be answered in this article.

Viral vectors are looking ahead a bright future in gene therapies. In this article, we give you an overview of the most frequently used viral vectors and have a glimpse at their possible future applications.

A great example is the treatment of insidious cancers with CAR T-cells, that relies on modifying the patient’s own T-cells to instill them with a targeted way to fight cancer cells. Learn more why forming strong collaborations will solve many issues!

Advanced cell-based assay workflow with CryoLogyx Thaw and Test pre-plated cell and controlled, scalable freezing process solution RoSS.pFTU to achieve effective cryopreservation of cells.

The production of AAVs requires to fulfill high standards and is thus in need of state of the art technologies. Find out what the key elements in the production of AAVs are and how our products help to carry them out.

Adeno-associated viruses are an increasingly important tool in biopharma, used for example as vectors for gene therapy and vaccines. But how are they adequately – and safely – handled? Here are some key aspects to consider along their supply chain.

Mastering the complex CAR T manufacturing process and the associated supply chain challenges in the cell and gene area are the major bottlenecks during the large-scale commercialization of highly promising CAR T cell products. 

Gene therapies have become a highly promising field of groundbreaking next generation treatment, but there are some challenges to face within the manufacturing process. Here are 5 factors that will be crucial for upscaling gene therapy manufacturing with single-use technology.

CAR T-cell treatments are deservedly on the rise, as the effectiveness of CAR T-cell products for formerly hard to treat hematology malignancies has been established in clinical trials. This article will highlight one of the less discussed issues of immunotherapy in cancer treatment: it’s current price tag could hamper the broad accessibility to patients.

In a comprehensive study the impact of ice front growth speed on scalability of freezing protein solutions has been evaluated.

In order to allow for a smooth and functioning process, a reliable supply chain, tailored to the specific needs of autologous therapies, is a prerequisite. Single Use Support has developed an end-to-end process solution for cell and gene therapies.